modelR06AX27

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Desloratadine
ATC code:R06AX27
route:oral
compartments:1
dosage:5mg
volume of distribution:49L
clearance:9.2L/h
other parameters in model implementation

Desloratadine is a non-sedating second-generation antihistamine used to treat symptoms associated with allergic rhinitis and chronic idiopathic urticaria. It is the active metabolite of loratadine and is widely approved and used today.

Pharmacokinetics

Pharmacokinetic parameters reported following single oral administration of 5 mg desloratadine in healthy adult volunteers.

References

  1. Liu, T, et al., & Liu, X (2024). Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole-Body Physiologically Based Pharmacokinetic Model. Journal of clinical pharmacology None –. DOI:10.1002/jcph.6120 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39171895

  2. Affrime, M, et al., & Cayen, M (2002). Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clinical pharmacokinetics 41 Suppl 1 21–28. DOI:10.2165/00003088-200241001-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12169043

  3. Simons, FE (2002). Comparative pharmacology of H1 antihistamines: clinical relevance. The American journal of medicine 113 Suppl 9A 38S–46S. DOI:10.1016/s0002-9343(02)01436-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12517581

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)